Category Archives: Healthcare

Wedbush Sticks to Their Buy Rating for Liquidia Technologies (LQDA)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $38.00. The company’s shares closed last Monday at $7.88. According to TipRanks.com, Moussatos is a

Mizuho Securities Downgrades Evolus (EOLS) to Hold

Mizuho Securities analyst Vamil Divan downgraded Evolus (EOLS – Research Report) to Hold today and set a price target of $3.00. The company’s shares closed last Monday at $5.32, close to its 52-week low of $3.12. According to TipRanks.com, Divan

Biospecifics Technologies (BSTC) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Biospecifics Technologies (BSTC – Research Report) today and set a price target of $100.00. The company’s shares closed last Monday at $62.31. According to TipRanks.com, Selvaraju is a top 100

Neoleukin Therapeutics (NLTX) Receives a Buy from H.C. Wainwright

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Neoleukin Therapeutics (NLTX – Research Report), with a price target of $22.00. The company’s shares closed last Monday at $14.35. According to TipRanks.com, Burns is

Chardan Capital Believes Akero Therapeutics (NASDAQ: AKRO) Still Has Room to Grow

In a report released today, Michael Morabito from Chardan Capital initiated coverage with a Buy rating on Akero Therapeutics (AKRO – Research Report) and a price target of $79.00. The company’s shares closed last Monday at $34.96, close to its

Otonomy (OTIC) Received its Third Buy in a Row

After Cowen & Co. and Piper Sandler gave Otonomy (NASDAQ: OTIC) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Francois Brisebois reiterated a Buy rating on Otonomy yesterday and set a price target